Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

Nov 14 2017

• By Emily Hayes

Listen to this article

In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival endpoint regardless of PD-L1 expression, supporting a bid for expanded labeling.

Bristol’s IO Pathways In Development — Bristol is developing many new immuno-oncology mechanisms, some of which were showcased at the SITC meeting in November. • Source: Bristol-Myers Squibb

Bristol-Myers Squibb Co. got a boost with promising data for its PD-1 inhibitor Opdivo in combination with drugs in a number of different classes, including the company's own assets – the CTLA-4 inhibitor Yervoy in first-line kidney cancer and its IDO inhibitor BMS 986205 in bladder cancer – plus Five Prime Therapeutics Inc.'s anti-CSF cabiralizumab in pancreatic cancer.

Bristol's highlights included an exploratory analysis of the Phase III CheckMate 214 study of Opdivo (nivolumab) with Yervoy (ipilimumab) in...

More from Immuno-oncology

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer
Sep 24 2025
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.
What To Look Out For At ESMO 2024
Mar 10 2025
• By Alexandra Shimmings
Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa
Mar 10 2025
• By Andrew McConaghie
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

More from Anticancer

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval
Mar 10 2025
• By Dexter Jie Yan
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Ordspono Will Be Regeneron’s First Independent European Launch
Mar 10 2025
• By Jessica Merrill
Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.